Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

EHA 2015

11 - 14 Jun 2015
Reed Messe, Vienna, Austria
Ibrutinib combined with bendamustine plus rituximab in previously treated CLL an...
Dr Paula Cramer - University of Cologne, Köln, Germany
Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL ( Dr Paula Cramer - University of Cologne, Köln, Germany )
30 Jun 2015
Chemoresistance and residual disease promoted by DNMT3A R882 in AML
Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA
Chemoresistance and residual disease promoted by DNMT3A R882 in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Jun 2015
Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL
Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands
Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL ( Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands )
17 Jun 2015
EHA 2015 highlights
Peter Goodwin - ecancer reporter
EHA 2015 highlights ( Peter Goodwin - ecancer reporter )
17 Jun 2015
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
Dr Jessica Okosun - Barts Cancer Institute, London, UK
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma ( Dr Jessica Okosun - Barts Cancer Institute, London, UK )
16 Jun 2015
Biomarkers for childhood relapsed acute lymphoblastic leukaemia
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Biomarkers for childhood relapsed acute lymphoblastic leukaemia ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
16 Jun 2015
Are CML patients being treated to the correct standard?
Dr Verena Hoffmann - Ludwig Maximilian University, Munich, Germany
Are CML patients being treated to the correct standard? ( Dr Verena Hoffmann - Ludwig Maximilian University, Munich, Germany )
16 Jun 2015
EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM
Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia
EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM ( Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia )
14 Jun 2015
Overview of innovation in Hodgkin's lymphoma
Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award
Overview of innovation in Hodgkin's lymphoma ( Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award )
14 Jun 2015
Applications of chimaeric antigen receptor T-cells in leukaemia
Dr Carl June - University of Pennsylvania, Philadelphia, USA
Applications of chimaeric antigen receptor T-cells in leukaemia ( Dr Carl June - University of Pennsylvania, Philadelphia, USA )
14 Jun 2015
Minimal residual disease in multiple myeloma
Dr Bruno Paiva - University Clinic of Navarra, Pamplona, Spain
Minimal residual disease in multiple myeloma ( Dr Bruno Paiva - University Clinic of Navarra, Pamplona, Spain )
14 Jun 2015
Immunoconjugates address unmet needs in Hodgkin's lymphoma patients
Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands
Immunoconjugates address unmet needs in Hodgkin's lymphoma patients ( Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2015
EHA 2015: Expert opinions on new treatment standard in multiple myeloma
Prof Pieter Sonneveld, Prof Antonio Palumbo, Prof Gordon McVie, Prof Thierry Fac...
EHA 2015: Expert opinions on new treatment standard in multiple myeloma ( Prof Pieter Sonneveld, Prof Antonio Palumbo, Prof Gordon McVie, Prof Thierry Facon )
13 Jun 2015
Exploring "bad luck" - why do some patients develop myeloid leukaemia?
Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK
Exploring "bad luck" - why do some patients develop myeloid leukaemia? ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )
13 Jun 2015
Genomic sequencing to find AML-causing mutations
Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK
Genomic sequencing to find AML-causing mutations ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )
13 Jun 2015
The latest in multiple myeloma: a European and US perspective
Prof Paul Richardson and Prof Marivi Mateos
The latest in multiple myeloma: a European and US perspective ( Prof Paul Richardson and Prof Marivi Mateos )
13 Jun 2015
Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid l...
Prof Susan Branford - Adelaide University Adelaide, Australia
Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia ( Prof Susan Branford - Adelaide University Adelaide, Australia )
13 Jun 2015
Advances in the treatment and management of CLL
Prof Clemens Wendtner and Prof Peter Hillmen
Advances in the treatment and management of CLL ( Prof Clemens Wendtner and Prof Peter Hillmen )
13 Jun 2015
Transplantation combined with novel agents optimal treatment for multiple myelom...
Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA
Transplantation combined with novel agents optimal treatment for multiple myeloma ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )
13 Jun 2015
Monoclonal antibodies and multiple myeloma
Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA
Monoclonal antibodies and multiple myeloma ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )
13 Jun 2015
New definition for multiple myeloma improves patient outcomes
Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA
New definition for multiple myeloma improves patient outcomes ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )
13 Jun 2015
Factors influencing response to blinatumomab in relapsed/refractory ALL
Prof Max Topp - Würzburg University Hospital, Würzburg, Germany
Factors influencing response to blinatumomab in relapsed/refractory ALL ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )
12 Jun 2015
Evidence for kinase inhibitor activity in acute myeloid leukaemia
Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany
Evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )
12 Jun 2015
Targeted combination therapy with potential to eliminate relapsed chronic lympho...
Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia
Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )
12 Jun 2015
DNMT3A R882 mutations promote chemoresistance and residual disease in AML
Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA
DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )
12 Jun 2015
New targeted combination therapy with potential to eliminate relapsed chronic ly...
Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia
New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )
12 Jun 2015
First randomised evidence for kinase inhibitor activity in acute myeloid leukaem...
Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany
First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )
12 Jun 2015
Does the patient with myelofibrosis feel better through pacritinib?
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Does the patient with myelofibrosis feel better through pacritinib? ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
12 Jun 2015
Adding elotuzumab to standard treatment for multiple myeloma significantly reduc...
Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens,...
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
12 Jun 2015
Treatment and survival of patients with chronic myeloid leukaemia in Europe
Dr Verena Hoffmann - Ludwig-Maximilians-Universität, München, Germany
Treatment and survival of patients with chronic myeloid leukaemia in Europe ( Dr Verena Hoffmann - Ludwig-Maximilians-Universität, München, Germany )
12 Jun 2015
Expert overview on the recent developments in mantle cell lymphoma
Professor Gordon McVie and Professor Simon Rule
Expert overview on the recent developments in mantle cell lymphoma ( Professor Gordon McVie and Professor Simon Rule )
12 Jun 2015